In clinical trials in TD patients, response to lenalidomide (ie, achievement of RBC-TI and Hb increase) was associated with improved HRQoL in patients who had lower-risk MDS with66,67 or without68 del(5q). Here, GSTM1 is linked to myelodysplastic syndrome.